Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo (GB)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by King Saud University.
Recruitment status was  Recruiting
University Hospital
Information provided by:
King Saud University
ClinicalTrials.gov Identifier:
First received: November 1, 2009
Last updated: November 4, 2009
Last verified: November 2009

Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.

Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.

Condition Intervention
Dietary Supplement: GINGKO BILOBA

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by King Saud University:

Primary Outcome Measures:
  • Repigmentation (more than 50% from baseline) as the primary outcome [ Time Frame: 3,6 and 9 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Quality-of-life - as secondary outcome . [ Time Frame: 3,6 and 9 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 160
Study Start Date: January 2009
Estimated Study Completion Date: January 2011
Intervention Details:
    Dietary Supplement: GINGKO BILOBA
Detailed Description:

Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL).

This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group).

One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly.

The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly.

Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups.

Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.


Ages Eligible for Study:   12 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  • Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo.
  • Body surface area (BSA) involvement ≥ 3%.

Exclusion Criteria:

  • Unable to consent
  • Any topical, systemic or phototherapy for Vitiligo in the previous 2 months.
  • Pregnancy, breast feeding.
  • Liver or kidney disease.
  • Epilepsy
  • Bleeding disorder or anticoagulant treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01006421

Contact: KHALID M ALGHAMDI, MD 4690815 kmgderm@yahoo.com

Saudi Arabia
King Khalid University Hospital Recruiting
Riyadh, Central, Saudi Arabia
Contact: KHALID M ALGHAMDI, MD    4690815    kmgderm@yahoo.com   
Principal Investigator: KHALID M ALGHAMDI, MD         
Sponsors and Collaborators
King Saud University
University Hospital
  More Information

Responsible Party: DR KHALID ALGHAMDI, KSU
ClinicalTrials.gov Identifier: NCT01006421     History of Changes
Other Study ID Numbers: GB-NBVUB 
Study First Received: November 1, 2009
Last Updated: November 4, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by King Saud University:
Gingko biloba

Additional relevant MeSH terms:
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on May 26, 2016